Beam Therapeutics: Pivoting From Platform To Execution Stage [Seeking Alpha]
Beam Therapeutics (BEAM) Valuation After FDA Alignment And Extended Cash Runway To 2029 [Yahoo! Finance]
Beam Therapeutics Advances Genetic, Hematology Pipeline, Extends Cash Runway to 2029; Shares Rise [Yahoo! Finance]
Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition [Yahoo! Finance]
Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition